Adjunctive Imipramine in the Treatment of Postpsychotic Depression: A Controlled Trial

doi:10.1001/archpsyc.1987.01800180043008

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Vol. 44 No. 6, June 1987

Online Only
	•	Online First Table of Contents

ORIGINAL ARTICLES

•	Online Features

This Article
•	References
•	Full text PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Citation map
•	Citing articles on HighWire
•	Citing articles on Web of Science (124)
•	Contact me when this article is cited

Related Content
•	Similar articles in this journal

Social Bookmarking
	What's this?

Adjunctive Imipramine in the Treatment of Postpsychotic Depression

A Controlled Trial

Samuel G. Siris, MD; Victoria Morgan; Richard Fagerstrom, PhD; Arthur Rifkin, MD; Thomas B. Cooper, MA

Arch Gen Psychiatry. 1987;44(6):533-539.

Abstract

• The efficacy of adjunctive imipramine hydrochloride treatmentfor syndromally defined postpsychotic depression was assessedin a six-week, double-blind, placebo-controlled study. All patientshad been diagnosed as having schizophrenia or schizoaffectivedisorder, all were receiving stable doses of fluphenazine decanoate,and all had received benztropine mesylate in an attempt to ruleout neuroleptic-induced akinesia. Patients randomized to imipraminetherapy fared significantly better in terms of their globalimprovement and in terms of individual symptoms that are componentsof the depression syndrome. There were no significant differencesin outcome psychosis ratings or side effects. This study indicatesthe existence of an identifiable syndrome of secondary depressionin this patient group that is likely to respond favorably totreatment with adjunctive imipramine.

Author Affiliations

From the Departments of Psychiatry (Drs Siris and Rifkin and Ms Morgan) and Biostatistics (Dr Fagerstrom), Mount Sinai School of Medicine, City University of New York; and the Nathan Kline Research Institute, Orangeburg, NY, and New York State Psychiatric Institute, New York (Mr Cooper).

Footnotes

Accepted for publication April 10, 1986.

Reprint requests to Mount Sinai Medical Center, KCC 1 South,One Gustave L. Levy Place, New York, NY 10029 (Dr Siris).

Add to CiteULike CiteULike Add to Connotea Connotea Add to Delicious Delicious Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes and the Schizophrenia Consensus Group of the British A
J Psychopharmacol 2011;25:567-620.
ABSTRACT | FULL TEXT

Psychiatric Comorbidities and Schizophrenia
Buckley et al.
Schizophr Bull 2009;35:383-402.
ABSTRACT | FULL TEXT

Suicide and schizophrenia
Siris
J Psychopharmacol 2001;15:127-135.
ABSTRACT

Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol
Tollefson et al.
Arch Gen Psychiatry 1998;55:250-258.
ABSTRACT | FULL TEXT

The drug treatment of patients with schizophrenia
DTB 1995;33:81-86.
ABSTRACT | FULL TEXT

Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty et al.
Arch Gen Psychiatry 1995;52:29-41.
ABSTRACT

Maintenance Imipramine Therapy for Secondary Depression in Schizophrenia: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1994;51:109-115.
ABSTRACT

Depressive Symptoms as Relative and Attributable Risk Factors for First-Onset Major Depression
Horwath et al.
Arch Gen Psychiatry 1992;49:817-823.
ABSTRACT

Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer et al.
Arch Gen Psychiatry 1989;46:922-928.
ABSTRACT

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Siris
Arch Gen Psychiatry 1988;45:1055-1055.
ABSTRACT

| | |